AGM
ZBIO

Alpine Global Management’s Zenas BioPharma ZBIO Stock Holding History

Alpine Global Management’s Portfolio ZBIO Stock Details ZBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-12,907
Closed -$125K – 305
2025
Q2 		$125K Buy
+12,907
New +$126K 0.03% 121

Other funds holding ZBIO

SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
NA
NVP Associates Menlo Park, California $176M AUM 208.78% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Alpine Global Management's ZBIO Position: Q3 2025 in Review

Alpine Global Management sold out of Zenas BioPharma (ZBIO) in Q3 2025, closing a stake of 12,907 shares — an estimated $125K sold.

Alpine Global Management first reported a position in ZBIO in Q2 2025 and held it in 1 quarter. The position peaked at $125K in Q2 2025. 80 funds tracked by Wall St. Rank hold ZBIO as of Q3 2025.

  • Alpine Global Management reported no remaining Zenas BioPharma position as of Q3 2025 after selling out during the quarter.
  • Alpine Global Management sold 12,907 Zenas BioPharma shares in Q3 2025, an estimated $125K.
  • Alpine Global Management first reported a position in Zenas BioPharma in Q2 2025 and held it in 1 quarter.
  • Alpine Global Management's Zenas BioPharma position peaked at $125K in Q2 2025.
  • 80 funds tracked by Wall St. Rank held Zenas BioPharma as of Q3 2025.

Based on Alpine Global Management's 13F filing for Q3 2025, filed 14 Nov 2025.